

September 13, 2021

BSE Limited
P. J. Towers
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E),
Mumbai - 400 051

Dear Sirs,

Sub.: Intimation of Investor/ Analyst Meetings

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be meeting the following Institutional Investors as per below schedule. The schedule may undergo change due to exigencies on the part of Investors/ Analysts/Company.

Date	Investors Name
14-Sep-21	New Vernon
14-Sep-21	White Oak
16-Sep-21	Old Bridge
17-Sep-21	Motilal MF

We also enclose the presentation to be used during our interaction.

This is for your information and record.

Thanking you,

Yours faithfully,
For Jubilant Ingrevia Limited

Deepanjali Gulati
Company Secretary

Encl.: as above



**JUBILANT
INGREVIA**

Investor Presentation September'21

Disclaimer



Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Effective 1st February 2021, Life Science Ingredients business of Jubilant Pharmova Limited (earlier Jubilant Life Sciences Limited) demerged to Jubilant Ingrevia Limited and post demerger the consolidated financial results of the Jubilant Ingrevia Limited for the quarter and the year ended 31 March 2021 comprised results only for two months of operations, starting from 1st February 2021 .

To provide the comprehensive picture of the operations of the Company on continuing basis the results for previous periods has been presented on Pro-forma basis by using relevant portion of the published results of LSI Segment - Jubilant Pharmova Limited on Pro-forma basis as Under :

- **Results Q1'FY21 has been derived on Pro-forma basis from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited.**
- **As explained in the Financial Results presentation deck for Q'4 FY 21 we had earlier presented results for fully year FY 21 on Pro-forma basis by combining the results from 01 April 2020 to 31 January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited and results for Q4'FY21 on Pro-forma basis by combining the results for January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited**
- **EPS for previous periods has been computed assuming existence of share capital throughout the period**

NOTES:

1. *The numbers for the quarter have been reclassified and regrouped wherever necessary*
2. *Closing Exchange Rate for USD 1 at Rs 73.11 as on March 31, 2021 and Rs 74.33 as on June 30, 2021*

Jubilant Bhartia Group - Snapshot

Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India



Strong presence in diverse sectors like Pharmaceuticals, Life Science Ingredients, Contract Research & Development Services and Therapeutics, Performance Polymers, Food Service (QSR), Auto, Consulting in Aerospace and Oilfield Services



Global presence through investments in India, USA, Canada, Europe, Singapore, China, Sri Lanka and Bangladesh



Employs around 46,000 people across the globe with Over 2,400 in North America

Jubilant Ingrevia: Glorious Four Decades of Growth

Our Journey

10+ years experience in Vitamin B3

20+ years experience in Vitamin B4 & premixes

30+ years experience in Pyridine Chemistry & value added Speciality products

40+ years leadership in Life Science products (Acetyls)

We started in 1978 as VAM Organic Chemicals. Over the years we built Global-Scale capacities

- 2019: Started new Acetic Anhydride plant, Bharuch SEZ, GJ (50 KTA)
- 2018: Started Agro Intermediate plant (800 TPA), Bharuch SEZ
- 2017: Certified for Responsible Care (RC)
- 2015: Commissioned speciality MPP plant (120 TPA), Gajraula
- 2013: Commissioned world class Chlorinated Pyridine plant (24 KTA), Bharuch SEZ

2021

Demerger into new entity **Jubilant Ingrevia**

2013-18

- 2012: Commissioned additional Acetic Anhydride capacity (50 KTA), Nira
- 2011: Started state-of-the-art GMP Vitamin B3 plant at Bharuch SEZ (14 KTA)
- 2009: Augmented capacity of Pyridine & Picolines plant (60 KTA)
- 2008: Certified for Pre-mixes Quality System FAMI-QS for Vitamins
- 2007: Commissioned additional Acetic Anhydride capacity (17 KTA), Nira
- 2006: Invested in Speciality & Multipurpose plants, Gajraula

2006-12

- 2000: Started Multi Product Plant (72 TPA), Gajraula
- Started Ethyl Acetate plant (20 KTA) in Nira, MH

2000

1999

Commissioned additional capacity of Pyridine & Picolines plant (6 KTA), Gajraula

Acquired Vitamin B4 (Choline Chloride) facility (10 KTA) at Samlaya, GJ

1990

1998

Started Acetic Anhydride (10 KTA), Acetic Acid (16 KTA), VAM (10KTA) plants at Gajraula, UP

Started Pyridine & Picolines plant (500 TPA), integrated with Aldehydes; Gajraula, UP

Acquired Nira facility in MH; with Acetic Acid (16.5 KTA), & VAM (10 KTA)




1978

1981



Business Segments & Integrated Operations



Integrated Operations...

Vertical integration across the value chain enables cost competitive advantage

Nutrition & Health Solutions

- For Vitamin B3 (Niacinamide & Niacin), 100% in-house sourcing of Beta Picoline (Key RM) from Speciality Chemicals

Speciality Chemicals

- ~45% of our Pyridine & Picolines volume is used in-house for value-added products in Speciality Chemicals & for Vitamin B3
- CDMO business supported through vertical integration

Life Science Chemicals

- 25% of overall volume of Life Science Chemicals is in-house consumed by Speciality Chemicals segment

1. The above segmental sales figures are taken from combined Pro-forma FY21 Financials

Executive Leadership Team



Rajesh Srivastava
Chief Executive Officer &
Managing Director
*34 years of
industry experience*



Anil Khubchandani
President –
Speciality Chemicals
*29 years of industry
experience*



R Kumar
President – Nutrition &
Health Solutions
*35 years of
industry experience*



Chandan Singh
President –
Life Science Chemicals
*35 years of industry
experience*



Prakash Bisht
President &
Chief Financial Officer
*32 years of
industry experience*



Anant Pande
President &
Chief of Operations
*35 years of industry
experience*



Vinita Koul
SVP &
Head- HR
*25 years of industry
experience*



Prasad Joglekar
EVP & Head –
Supply Chain
*28 years of industry
experience*

Leadership team has an average 30 years of industry experience

Jubilant Ingrevia: Company Snapshot

Business Segments	Leadership
Speciality Chemicals	- Amongst top 2 in (Pyridine + Beta Picoline) - Globally # 1 in 11 Pyridine Derivatives
Nutrition & Health Solution	-Amongst top 2 Globally in Vit B3 (Niacinamide) - Leader in India Vit B4 (Choline Chloride)
Life Sciences Chemicals	Globally - Amongst top 2 in Acetic Anhydride - Largest manufacturer of bio-based Acetaldehyde

Revenue Segmentation: By Region

Total 1400+ customers
• Speciality Chemicals: 420
• Nutrition & Health Solutions: 400
• Life Science Chemicals: 600

Total 165+ products
• Speciality Chemicals: 85
• Nutrition & Health Solutions: 72
• Life Science Chemicals: 8

Sales in over **50** countries with **25%** of sales in regulated markets such as US, Europe, Japan - leading to sustainable revenue

Diverse Industry End-Use


FY'21 Revenue Split

Pharma	Agro	Paints & Coatings
Animal Feed	Packaging	Vitamins
Vitamins	Cosmetics	Antimicrobial

Key Highlights


Financials (FY'21) Revenue ₹ 3,491 Cr. EBITDA ₹ 627Cr.(17.9%) Net Debt / EBITDA rate of 0.7x	Expertise in 35 Technology platforms (At large commercial scale)	Expertise in handling multi-step chemistries (Up to~13 steps) At Commercial scale	5 Global scale Manufacturing sites with 50 plants
Globally Lowest cost producers - Most products due to backward integration	Capability in handling large "Ketene" volumes through Acetic Anhydride	In line with our Vision to double the Revenue by FY'26, we have 60+ Products in Pipeline.	Global workforce of ~2100 employees
Offices in India, US, Europe, Japan & China			

Strong Presence in Industry Value Chain






Industry Overview: Presence in Large & Growing Markets

Speciality Chemicals






1. Indian market for Speciality Chemicals does not include share of PCP & 2,3-DCP

Nutrition & Health Solution



2) Sum of Vit Feed Supplements+ Functional Food Ingredients + Nutraceuticals + Pet Food + Feed Additives

Life Science Chemicals



3) Merchant Market

BUSINESS SEGMENTS

Speciality Chemicals – Segment Snapshot

85 Products <i>(Pyridines & Picolines, Cyanopyridines, Piperidines, Aminopyridines, Lutidines)</i>	Amongst top 2 Globally in (Pyridine+Beta), - Globally #1 in 11 Pyridine Derivatives	Globally lowest cost producer of Pyridine offering significant long term advantage
Market size (in JVL Products): \$ 1221 Mn JVL Market Share: ~13%	25 plants across 3 Sites	Products are REACH, HALAL & KOSHER certified

Diverse Industry End-Use

FY'21 Revenue Split

Pharma	Agro
Nutrition	Microbial Control
Paints & Coatings	Solvent

Region wise Revenue Segmentation (FY'21)

Domestic Sales for International Consumption 17%

Domestic Sales for Domestic Consumption 27%

“Partner of Choice” to ~420 global customers
 Serving 15 of top 20 Global Pharma & 7 of top 10 Global Agrochemical companies

International reach through offices in US, Europe, Japan & China

Around 40% export in regulated markets leading to sustainable revenue

Key Investment Projects


- Diketene & Derivatives (Q4 FY'22)**
- CDMO GMP & Non – GMP Facility (Q1 FY'23)**
- MPP - Insecticides/ Fungicides/ Herbicide (Q4 FY'23)**

Investment of **~INR 550 Cr.** by FY'24

In line with our Vision to double the Revenue by FY'26, we have **36 Products** in Pipeline.


Nutrition & Health Solutions – Segment Snapshot

<p>5 Nutrition Ingredients & 18+ branded solutions (For Animal Health)</p>	<p>Global top 2 in Vitamin B3 Domestic leader in Vitamin B4 (Feed)</p>	<p>100% in-house sourcing of Beta Picoline (Key RM) for Vitamin B3 via green route</p>
<p>19% Global market share in Vitamin B3 60% domestic share in Vitamin B4</p>	<p>5 Plants across 2 Sites</p>	<p>WHO GMP, FSSAI, HALAL, KOSHER and FAMI-QS certified</p>



Key Investment Projects

- Nutrition Premix Plant expansion for Animal Nutrition (Q2 FY'23)**
- Facility upgrade for Pharma Grade Vit B3 (USFDA, EU CEP) (Q3 FY'23)**
- Niacinamide Capacity Expansion (Q1 FY'24)**



“Partner of Choice” to ~400 global customers and has established strong distribution network

Globally, we serve **90+** customers in Cosmetics, **55+** Customers in Dietary supplements & **20+** Customers for Energy Drinks and Breakfast Cereals.

Strategic partnership for the Human Nutrition line of products


More than half of the exports in regulated markets leading to sustainable revenue

Investment of **~INR 100 Cr.** by FY'24

In line with our Vision to double the revenue by FY'26, we have **18 Products** in Pipeline.

Life Sciences Chemicals – Segment Snapshot


8 Products <i>(Acetic Anhydride, Ethyl Acetate, Propionic Anhydride, Aldehydes, Speciality Alcohol, Anhydrous Alcohol)</i>	Leadership in merchant market of Acetic Anhydride and Propionic Anhydride	Among top suppliers of Fuel grade Ethanol to Oil Marketing Companies
9% Global market share in LSI & 10% domestic share in Speciality Alcohol	20 plants across 3 Sites <i>(Multi-location, Multi-plant advantage)</i>	Products are REACH, HALAL & KOSHER certified



- ### Key Investment Projects
- Food grade Acetic Acid plant (Q1 FY'23)**
 - Acetic Anhydride capacity expansion (Q4 FY'23)**

Investment of ~ **INR 250 Cr.** by FY'24

In line with our Vision to double the Revenue by FY'26, we have **7 Products** in Pipeline.



☀️ **"Partner of Choice"** to ~600 global customers

European Union is the major deficit market: nearly **90%** import dependent for Acetic Anhydride; nearly **70%** import dependent for Ethyl Acetate.

☀️ India Pharma and Agro applications are estimated to witness strong growth, mainly driven by Paracetamol, Acephate and Ibuprofen.

☀️ Shift of manufacturing from China to India will encourage growth in various industrial applications in India.

Multi Location Manufacturing & Operation Excellence



Manufacturing Facilities



463 acres

Gajraula, Uttar Pradesh, India

Integrated facility for Speciality Chemicals & Life Science Chemicals



310 acres

Bharuch, Gujarat, India

Speciality Chemicals, Nutrition & Health Ingredients & Life Science Chemicals facility located in SEZ



144 acres

Nira, Maharashtra, India

Life Science Chemicals



109 acres

Samlaya, Gujarat, India

Animal Nutrition & Health Solutions



3.5 acres

Ambernath, Maharashtra, India

Speciality Chemicals

International offices in US, Europe, Japan & China

▪ We operate 50 Plants across 5 sites in 3 states



RC 14001:2015
Gajraula, Bharuch & HO Noida

Operation Highlights

Multi-Chemistry, Multi-Product and Process Condition handling expertise

Large capacities in **Continuous & Batch processes**

World Class GMP facility at Bharuch

Temp, Humidity & Differential Pressure Controlled Areas with ISO-8 (Class 100,000) Clean rooms

cGMP compliant Pilot Plant

20 – 1000L Reactors (Glass Assemblies, Cryogenic & Plug Flow reactors, Lyophilizer Autoclaves)

In-house Utilities

Captive Power Plant (Gajraula), Own Steam Generating Boilers, Chilled Water & Brine Unit

Ecologically Harmonized Practices

Incinerators, ETPs, Multi Effect Evaporators, Reverse Osmosis, Water Polishing Plants

Health & Safety:

benchmarking global performance by Chilworth Dekra- FY'07 & Chola MS- FY'21

Compliance: 3,800+ compliance items through 'EY' Conformity tool

Jubilant Ingrevia: Global Accreditation



Select Certifications	Gajraula	Bharuch	Nira	Samlaya	Ambernath
No. of plants	36	5	13	5	2
 Responsible Care RC 14001:2015	✓	✓			
 ISO 9001:2015	✓	✓	✓	✓	✓
 ISO 22000:2005	✓	✓	✓		
 ISO 14001:2015	✓	✓	✓	✓	
 ISO 45001:2018	✓	✓		✓	
 FSSAI	✓	✓	✓	✓	
 FAMI-QS		✓		✓	
 HALAL KOSHER	✓	✓	✓		
 GMP Certification	✓ State FDA GMP	✓ State FDA GMP & WHO GMP			
 TFS Audit		✓ (FY'19)	✓ (FY'20)		



Certification for Jubilant Life Sciences Ltd.: FY'20 (Gold Category)

Business Excellence and Digital Transformation

Belt Competencies (FY'21)

Black Belts: 08

Green Belts: 98

Yellow Belts: 141

Business Excellence (17+ years experience)

Design Excellence

Strengthen Development Capability by exploring complete design space and target Right First Time

Operational Excellence

- Removing process inefficiencies
- improve cost effectiveness
- Addressing process variation
- Improve asset utilization

Customer Excellence

- Effective time & cost management for customer's NPD projects
- Analytics for accurate forecasting

Tools & Processes

Theory of Constraints

Quality by Design

Mission Directed Team

Balanced Scorecard

Six Sigma

Lean

TPM

Process Engineering

CRM

Analytics

Stage Gate deployment

Customer Dashboard

Digital Transformation

- Our journey started in 2018 with an objective to **improve**
 - Operational efficiency
 - Business & Supply chain processes
 - customer experience and engagement
- Every project we consider is based on the individual business case



Sustainability

- Energy Demand Forecasting
- Electronic Production Management
- Demand & Production Planning
- Digitally Accelerated Contract Manufacturing



Efficiency Improvement

- Upgradation & Security enhancement of ERP
- Process Automation
- Employee Collaboration
- Digital Factory



Customer Engagement

- Customer Experience
- Digital Sales through Salesforce Automation & Project & Workflow Management Platforms

Research Development & Technology (RDT)



Key Highlights



3 RDT centers in Noida, Gajraula and Bharuch



35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Grignard etc.



90 highly qualified scientists (~20 PhDs)




> 65 New Products Pipeline for next 5 years

Key Technology Platforms

1000s MT	100s MT	MTs
Aromatization	Sandmeyer	Hoffmann
Oxidation	Grignard	Re-arrangement
Vapour Phase Reactions	Bromination	Bu-Li Reaction
Ammoxidation,	Methylation	Iodination
Fermentation	Thiol Handling	Chiral Synthesis
Ketene Technology	Esterification	N-Formylation
Chlorination / Photochlorination	Quarternisation	De-alkylation
	Ethylene Oxide Reaction	
	Hydrogenation	
	Chichibabin	

Key focus areas for RDT



CSR - Jubilant Bhartia Foundation

Established
in 2007

Mission: To develop multi-stakeholder sustainable models to bring about 'social change' involving knowledge generation & sharing, experiential learning & entrepreneurial ecosystem



A sister organization of World Economic Forum in Partnership with Jubilant Bhartia Foundation

Education



- **50,000** students in **275** govt. primary schools
- Developed **digital platform** "Jubilant Education System"
- Introduced **Digital Classes** in Government schools

Improving Health



- **Jubilant Aarogya** - Affordable healthcare services
- **Swasthya Prahari** – Conduction Growth Monitoring of **10,000+ children** from 0 to 5 yrs of age and BCC to decrease malnutrition

Escalating Employability



- Skill Development program for **training 2500 youth** every year.
- Promote Self sustainable Micro Enterprise

Social Entrepreneurship



- JBF with **the Schwab Foundation** recognize & **award exceptional individuals in Social Business**
- Providing business to social enterprises


FACE- Centre for Excellence



An initiative between **CII & Jubilant Bhartia** to improve productivity of agriculture and increase farmer income



Sustainability Journey



- **37%** Reduction in Specific Water Consumption wrt FY 13
- **3 out of 5** sites are Zero Liquid Discharge
- **27%** Reduction in Specific Greenhouse Gas Emissions wrt FY 13
- **25%** Reduction in Specific Energy Consumption wrt FY 13
- **44964** Training man-days were imparted from FY 14
- **870 families** supported by providing sustainable livelihood
- **20 schools** Digitization completed
- **1,70,000** Trees planted

Our sustainability goals Alignment with UN Sustainable Development Goals (SDGs)

1 NO POVERTY 	2 ZERO HUNGER 	3 GOOD HEALTH AND WELL-BEING
4 QUALITY EDUCATION 	5 GENDER EQUALITY 	6 CLEAN WATER AND SANITATION
7 AFFORDABLE AND CLEAN ENERGY 	13 CLIMATE ACTION 	17 PARTNERSHIPS FOR THE GOALS



For more detail visit our Sustainability page
<https://jubilantingrevia.com/about-us/sustainability>

#JubilantCares | Stronger Together | Our Efforts during Pandemic



Oxygen Support during Crisis



Provided **oxygen cylinders & concentrators** at doorsteps of employees in need & installed Oxygen plant.

Ambulances & Hospital Assistance




Provided **Assistance in arranging ambulances and hospital beds** for employees and their families

Isolation Centers



Company aided isolation centers at Noida, Mumbai, Indore & Chennai with medical assistance

Vaccination Drive



Massive Vaccination drive across India for all our employees & their families

RTPCR Testing Camps



Organized RTPCR Testing camps at our corporate offices & site offices

Yoga & Wellness



Appointed **Yoga & wellness experts** to help our employees deal stress during these tough times

EWAP



Launched **Employee Well-Being and Assistance Program**

Doctors On Call



24*7 Doctor On Call facility for all employees

Financial Support



Put together a **strong ex-gratia financial package** to support the families of our deceased employees

Financials


Jubilant Ingrevia – Q1'FY22 Financial Highlights




Particulars ¹	Q1'FY21 ²	Q1'FY22	YoY (%)
Revenue			
Speciality Chemicals	257	305	18%
Nutrition & Health Solutions	148	167	13%
Life Science Chemicals	331	673	103%
Total Revenue from Operations	737	1,145	55%
Reported EBITDA	127	287	126%
Speciality Chemicals	69	84	22%
Nutrition & Health Solutions	31	27	(15%)
Life Science Chemicals	24	184	677%
Unallocated Corporate (Expenses)/Income	3	-7	-
PAT	53	168	220%
EPS	3.3	10.6	220%
Reported EBITDA Margins	17.3%	25.1%	
Speciality Chemicals	26.8%	27.7%	
Nutrition & Health Solutions	21.0%	15.9%	
Life Science Chemicals	7.1%	27.3%	
Net Margin	7.1%	14.7%	

- Revenue grew by 55% on YoY basis, driven by robust growth in volume and prices.
- Speciality Chemicals revenue grew by 18% YoY driven by volume growth across product segments.
- Nutrition and Health Solutions revenue grew by 13% YoY driven by higher volumes and growth in Niacinamide price
- Life Sciences Chemical revenue grew by 103% YoY, driven by higher prices on account of favorable market conditions and pass-on of higher input cost of acetic acid
- EBITDA at Rs 287 Crore, grew by 126% on account of strong performance of Speciality Chemical & Life Sciences chemical segment led by favorable market conditions.
- PAT grew by 220% YoY driven by growth in EBITDA, added by reduction in finance cost by Rs 15 Crore through reduction in average debt by Rs 706 Crore and decrease in Interest rate by 0.75% , partially set off by higher tax expense.

Q1'FY22 Geographical Revenue Split



Q1'FY22 Industry End-Use Split



1. All figures are in Rs Crore unless otherwise stated
 2. - Q1'FY21 is derived from 3 month of discontinued operation of LSI segment of Jubilant Pharmova Limited on Pro-forma basis
 - EPS has been computed on combined profits assuming existence of share capital for full period.

Debt Profile – Q1 FY22

Particulars ¹	31/Mar/21	30/Jun/21
Long Term Borrowings	456	227
Short Term Borrowings	92	230
Total	548	457
Cash & Equivalent	117	70
Net Debt	431	386
QoQ change	-	-10%


- Gross Debt reduction of Rs 91 Crore in Q1'FY 22.
- Net Debt reduction of Rs 45 Crore in Q1'FY22.
- Net Debt to EBITDA in Q1'FY22 stands at 0.5 times, from the earlier lever of 0.7 times as on 31st March, 2021.
- Average blended interest rate for Q1'FY22 was 7.09%, against 7.84 % in Q1'FY21 and average debts during Q1'FY 22 was lower by Rs 706 Crore as compared to Q1' FY 21.

Jubilant Ingrevia Limited – FY21 Financial Highlights (Pro-forma²)


Particulars ¹	FY20	FY21	YoY (%)
Revenue			
Speciality Chemicals	1,104	1,124	2%
Nutrition & Health Solutions	537	630	17%
Life Science Chemicals	1,537	1,738	13%
Total Revenue from Operations	3,179	3,491	10%
Reported EBITDA	409	627	53%
Speciality Chemicals	237	268	13%
Nutrition & Health Solutions	95	130	37%
Life Science Chemicals	99	236	138%
Unallocated Corporate (Expenses)/Income	-22	-8	
PAT	220	316	43%
EPS	13.8	19.9	43%
Reported EBITDA Margins	12.9%	17.9%	
Speciality Chemicals	21.4%	23.9%	
Nutrition & Health Solutions	17.7%	20.7%	
Life Science Chemicals	6.5%	13.6%	
Net Margin	6.9%	9.1%	

- Revenue grew by 10% on YoY basis, driven by growth in volume and pricing both.
- Speciality Chemicals revenue grew by 2% YoY driven growth in Fine Chemicals and new CDMO projects
- Nutrition and Health Solutions revenue grew by 17% YoY driven by conducive market condition and robust growth in Niacinamide prices
- Life Sciences Chemicals revenue grew by 13% YoY driven by favorable market conditions from Pharma, Packaging, Industrial applications both in domestic as well as export markets
- EBITDA at Rs 627 Crore, grew by 53% YoY
- PAT grew by 43% YoY driven by growth in EBITDA and reduction in finance cost through reduction in debt as well as interest rates
- PAT is after reduction of Exceptional items of Rs 13 Crore
- RoCE improved to 20.2% in FY21, from 12.0% in FY20, driven by increase in EBIT and optimization of working capital
- RoE stood at 16.4% in FY21

FY21 Geographical Revenue Split




FY21 Industry End-Use Split




1. All figures are in Rs Crore unless otherwise stated
2. - FY21 is calculated from 10 month of discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months of Jubilant Ingrevia Limited
 - FY20 is calculated from 12 month of discontinued operation of LSI segment of Jubilant Pharmova Limited
 - FY20 Segment EBITDA without Adjusting unallocated Corporate Expenses was Rs 431 Crore
 - EPS has been computed on combined profits assuming existence of share capital for full year.

Balance Sheet – Key Parameters/Ratios (Pro-Forma²)


Return On Capital Employed (RoCE)




Return on Equity




Asset / Turnover and Return On Asset (RoA)



Net Working Capital



Operating Cash flow and Capex



- Strong Balance Sheet:
 - RoCE improved significantly to 20.2%
 - RoE for FY21 stood at 16.4%
 - Asset to Turnover increased to 2x in FY21 from 1.8x in FY20
- RoCE and Assets Turnover ratio for FY20 was low due to commissioning of new Acetic Anhydride plant in FY20
- COVID-19 impact on working capital in FY20 corrected in FY21

1. All figures are in Rs Crore unless otherwise stated

2. - FY21 is calculated from 10 month of discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months of Jubilant Ingrevia Limited
 - FY20 is calculated from LSI segment of Jubilant Pharmova Limited before unallocated expense/assets.

Our Vision, Values, Promise and Philosophy

OUR VISION

- To acquire and maintain global leadership position in chosen areas of businesses
- To continuously create new opportunities for growth in our strategic businesses
- To be among the top 10 most admired companies to work for
- To continuously achieve a return on invested capital of at least 10 points higher than the cost of capital

OUR PROMISE

Caring, Sharing, Growing

We will, with utmost care for the environment and society, continue to enhance value for our customers by providing innovative products and economically efficient solutions; and for our stakeholders through growth, cost effectiveness and wise investment of resources

OUR VALUES



OUR PHILOSOPHY



Caring



Sharing



Growing

Thank you

For Investors:

Pavleen Taneja

Ph: +91 120 436 1021

E-mail: pavleen.taneja@jubl.com

For Media:

Sudhakar Safaya

Ph: +91 120 436 1034

E-mail: sudhakar.safaya@jubl.com

Siddharth Rangnekar

CDR India

Ph: +91 22 6645 1209

E-mail: siddharth@cdr-india.com

Clayton Dsouza

Madison Public Relations

E-mail: clayton.dsouza@madisonpr.in

Phone number: +91 9930011602

Thank you for your time

Jubilant Ingrevia Limited

1A, Sector-16A, Noida - 201 301, Uttar Pradesh, India

Email: support@jubl.com | www.jubilantingrevia.com

Appendix

Pro-Forma Income Statement Consolidated – FY21 (10 months discontinued operation of LSI segment of Jubilant Pharmova Limited and 2 months Jubilant Ingrevia Limited)



Particulars ¹	FY20	10M'FY21 Apr'20 to Jan'21	2M'FY21 Feb'21 to Mar'21	FY21	YoY (%)
Revenue from operations					
a) Sales/Income from operations	3,134	2,786	679	3,465	11%
b) Other operating income	45	21	5	27	(41%)
Total revenue from operations	3,179	2,807	684	3,491	10%
Other income	10	12	3	15	48%
Total income	3,189	2,819	687	3,506	10%
Expenses					
a) Cost of materials consumed	1,681	1,324	363	1,688	(0%)
b) Purchases of stock-in-trade	122	83	16	99	18%
c) Changes in inventories of finished goods, stock-in-trade and work-in progress	-118	59	-10	49	(142%)
d) Employee benefits expense	284	250	49	299	(5%)
e) Other expenses:					0%
- Power and fuel expense	362	272	52	324	11%
- Others	448	324	96	420	6%
Total expenses	2,779	2,312	567	2,879	(4%)
EBIDTA	409	507	120	627	53%
Depreciation and amortization expense	122	103	22	125	(2%)
EBIT	287	404	98	502	75%
Finance costs	88	63	7	71	20%
Profit before exceptional items and tax (3-4)	199	341	90	431	116%
Exceptional items	2	-	13	13	(661%)
Profit before tax (5-6)	198	341	77	418	112%
Tax expense	-23	79	-23	56	
Net Profit for the period (7-8)	220	262	54	316	43%

1. All figures are in Rs Crore unless otherwise stated 2. FY20 Segment EBITDA without Adjusting unallocated Corporate Expenses was Rs 431 Crore